BIO.B — Bio Rad Laboratories Income Statement
0.000.00%
Last trade - 00:00
- $7.87bn
- $7.46bn
- $2.67bn
2019 December 31st | R2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,312 | 2,546 | 2,923 | 2,802 | 2,671 |
Cost of Revenue | |||||
Gross Profit | 1,261 | 1,438 | 1,663 | 1,568 | 1,431 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 2,088 | 2,117 | 2,423 | 2,330 | 2,333 |
Operating Profit | 224 | 428 | 500 | 472 | 338 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 2,261 | 4,918 | 5,449 | -4,704 | -850 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1,759 | 3,814 | 4,254 | -3,628 | -637 |
Net Income Before Extraordinary Items | |||||
Net Income | 1,759 | 3,814 | 4,254 | -3,628 | -637 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1,759 | 3,814 | 4,254 | -3,628 | -637 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 59.1 | 126 | 143 | -121 | -21.2 |